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Transplantation is invariably associated with ischemia reperfusion injury (IRI) which causes 
organ dysfunction. IRI is also directly linked to several forms of programmed cell death 
including apoptosis and necroptosis, which increase kidney dysfunction, promote 
inflammation and may contribute to premature graft failure. The contribution of necroptosis 
and apoptosis following kidney IRI to cell-free DNA (cfDNA) generation and the potential of 
cfDNA to activate effectors such as NK cells involved in kidney IRI have not been defined. 
Our data indicate that necroptotic microvascular endothelial cells (MVECs) release 
considerably more cfDNA than apoptotic MVECs or untreated controls (p<0.0001). cfDNA 
was readily detected in serum following kidney IRI in vivo. RIPK3 deficiency modestly 
inhibited cfDNA release post-IRI. Levels in genetically altered mice incapable of both 
apoptosis and necroptosis (RIPK3-/-/caspase-8-/-, DKO) were comparable to sham controls 
(n=7, p<0.0001). cfDNA also appears to be a sensitive biomarker of injury as serum levels 
were reduced even with small reduction in IRI model temperatures (n=4, p<0.01). 
Furthermore, cfDNA was detectable in subclinical IRI at 24-28°C, in which serum creatinines 
remained in the normal range (n=4, p<0.0001). Lastly, NK cells, well described effectors of 
IRI, upregulated key activation markers Granzyme B (p<0.0001), IFNγ (p<0.0001), and TNFα 
(p<0.01) when treated with cfDNA (n=4). As such, cfDNA is a sensitive biomarker of cellular 
injury that is also able to activate NK cells and can promote IRI-associated inflammation. 
Strategies that reduce inflammatory injury and necroptosis that release cfDNA would be 











Summary for Lay Audience 
 
Transplantation is invariable associated with injury to the donor organ. During this injury 
various forms of cell death occur, and contribute to organ injury. During this cell death, 
molecules are released from dying cells in a controlled fashion. One such molecule that has 
generated interest is termed cell-free DNA (cfDNA), as it is released from dying cells, and is 
also capable of stimulating the immune system. We have shown that cfDNA is released by 
dying cells by a variety of different cell death programs. We have also shown that cfDNA is 
released into the blood in a mouse model of transplant-associated organ injury, and that this 
release of cfDNA can be limited when certain forms of cell death are genetically impaired. 
We have also shown that cfDNA is a more sensitive marker of organ injury than currently 
used clinical standards, such as the measurement of serum creatinine levels. Lastly, we have 
shown that immune cells, NK cells in particular, are activated by cfDNA, which may 
therefore be promoting inflammation in the transplant recipient. As such, we have shown that 
cfDNA is a sensitive biomarker of cellular injury that is also capable of activating the 
immune system, thereby promoting inflammation. Strategies to reduce the release of cfDNA 
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Chapter 1  
1 INTRODUCTION 
 
1.1 Challenges in Kidney Transplantation 
Chronic Kidney Disease (CKD) is a global health problem that imposes a large 
burden on the healthcare system and on society (1). During the early stages of CKD, some 
forms of kidney pathology can be reversed and kidney function can improve with a change 
in diet, lifestyle, as well as with the administration of medications (2). However, once 
kidney function drops below 15%, complications of CKD begin to occur, and these include 
hypertension, malnutrition due to poor reabsorption of nutrients from the blood, bone 
disease, heart failure, and neuropathy (3). If not treated, progression will lead to End Stage 
Renal Disease (ESRD) which requires treatment to avoid death (3). Once the patient has 
progressed to ESRD, only two treatment options are available: dialysis and kidney 
transplantation (4). Numerous clinical studies indicate that kidney transplantation is by far 
the preferred treatment for most patients with ESRD, with transplant recipients 
experiencing decreased mortality as well as increased quality of life when compared to 
patients who receive dialysis (5,6). Indeed, the data show that receiving a kidney transplant 
can prolong life expectancy by 10-15 years compared to dialysis alone (7). Despite the 
overwhelming superiority of transplantation to dialysis, transplantation-related 
complications can arise that can lead to kidney allograft loss or injury (7). 
The success of a renal transplant is multifactorial, with both immunological and 
non-immunological factors coming into play. Non-immunological factors that affect renal 
transplant success include drug toxicity, donor organ viability, and host/recipient factors 
(8). The viability of the donor organ can be affected by age of the donor, renal mass, the 
amount of time the donor organ is deprived of blood supply, presence or absence of donor 
brain injury, and whether the donor was living or deceased at the time of procurement (8). 
Similarly, the overall health of the recipient directs survival. If the recipient of the 
transplant has a lipid disorder (i.e. hypercholesterolemia), diabetes, high blood pressure, or 
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any circulatory obstructions (i.e. an atherosclerotic plaque), then the likelihood of success 
of the graft can be reduced (8). Immunological factors that affect transplant success include 
cellular immunity, antibody-mediated (formerly referred to as humoral) immunity, and 
infection (8). Cellular immunity is triggered by direct or indirect allorecognition and from 
a failure of immunosuppression to adequately reduce the alloimmune response of the 
recipient (8). Antibody immunity is related to antibody-mediated rejection of the donor 
tissue, or if the recipient has been sensitized to donor antigens prior to the transplant (8). 
Lastly, although immunosuppression is critical and unavoidable in the setting of a 
transplant, it also has the unintended side-effect of a ‘weakened’ host immune system, 
increasing the risk of opportunistic viral, bacterial, and fungal infections that would 
typically not be of concern in a non-immunocompromised individual. 
Preventing allograft responses and rejection by the recipient immune system 
remains a key target in kidney transplantation (9). The recipient immune system recognizes 
the donor organ as foreign by targeting the highly variable major histocompatibility 
complex (MHC) molecules [aka human leukocyte antigens (HLA), as they are referred to 
in humans] (10). For this reason, HLA matching between organ donor and recipient is 
important, as matching will significantly reduce the chance of graft rejection, but it is of 
less priority than medical urgency or waiting time (10). 
1.2 Ischemia Reperfusion Injury 
One particularly critical early type of allograft injury that occurs invariably with 
transplant is ischemia reperfusion injury (IRI) (11). IRI is a major cause of delayed graft 
function in transplant recipients, and can even lead to early graft loss via severe acute renal 
failure (ARF) (12). Ischemia occurs when the blood vessels in the donor tissue are clamped, 
thereby removing blood supply to the organ, and creating an environment that lacks both 
oxygen and nutrients (13). Reperfusion occurs when blood flow is restored to the organ. 
This influx of oxygen during the reperfusion stage results in the formation of reactive 
oxygen species (ROS) which promote inflammation (13). The oxidative stress resulting in 
increased levels of ROS causes the upregulation of pro-inflammatory cytokines and 
chemokines. The upregulation of these cytokines and chemokines causes increased 
vascular permeability as well as an increase in the expression of endothelial cell adhesion 
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molecules, which will act to recruit and activate infiltrating leukocytes to the graft (14, 15). 
Furthermore, oxidative damage caused by ROS will trigger the activation of toll-like 
receptor (TLR) and complement arms of the innate immune system, furthering the damage 
to the graft (16). For example, the release of endogenous ligands, known as damage 
associated molecular patterns (DAMPs) from damaged cells during IRI will bind and 
activate numerous TLRs of resident dendritic cells (17). Complement induction is mediated 
through the reduced expression of complement regulatory proteins on the surface of tubular 
epithelial cells (TECs) and microvascular endothelial cells (MVECs) of the allograft (18, 
19). Both the induction of the complement system and the activation of TLRs will induce 
resident dendritic cells of the allograft to produce even more pro-inflammatory chemokines 
and cytokines, triggering earlier and more robust immune responses against the allograft 
(16). Part of this immune response to IRI is the infiltration of macrophages, neutrophils, 
and natural killer (NK) cells into the graft (20-22). These infiltrating innate immune cells 
can release more ROS, as well as proteases, cytokines and chemokines which will recruit 
additional immune cells and will induce undesirable and unbalanced programmed cell 
death of the resident tissue cells (22), all contributing to increased inflammation, increased 
IRI, and increased acute allograft injury in a cyclical fashion. It is a cycle of inflammation 








Figure 1. Innate inflammatory cycle during IRI. 
During IRI, cells of the kidney allograft are injured as a result of increased ROS as well as 
due to host immune responses, leading to DAMP release from cells of the allograft. 
Released DAMPs then bind to TLRs on resident dendritic cells which will release pro-
inflammatory chemokines and cytokines, resulting in the infiltration of macrophages, 
neutrophils and NK cells. Infiltrating innate cells release even more ROS, as well as 







1.3 Leukocyte Function and Biology in IRI 
A diverse population of leukocytes are implicated in the damage caused by IRI. 
Firstly, CD4+ T cells infiltrate the kidney allograft as early as 4 hours post-ischemia (20). 
In addition to this early recruitment of T cells, CD19+ B cells, resident dendritic cells, 
macrophages, neutrophils, and NK cells also infiltrate the kidney allograft (21). 
Macrophages are recruited by activated resident dendritic cells and will infiltrate the graft 
and secrete cytokines such as interferon-gamma (IFN-) (22). Cytokine release by 
macrophages will induce programmed cell death of cells of the allograft, as well as recruit 
neutrophils. Neutrophils will also cause damage to the graft as they are potent effector cells 
that cause damage by obstructing the renal microvasculature, as well as by the release of 
ROS and proteases (20). Of all these infiltrating leukocytes implicated in the damage 
caused by IRI, NK cells are particularly understudied. 
NK cells are a subset of leukocytes that are derived from bone marrow-resident 
lymphoid progenitor cells, and are a component of the innate immune system (23). As their 
name suggests, NK cells are ‘killer’ cells that are typically capable of killing abnormal host 
cells, such as tumour cells and viral-infected cells, as well as foreign cells (24). NK cells 
are able to induce cytotoxicity via the release of perforin and granzyme as well as through 
the expression of Fas ligand (25). Perforin is a pore-forming protein that essentially creates 
holes in target cells which allows for the delivery of various granzyme family members 
(25). Granzyme is a protein family consisting of structurally-related serine proteases that 
are capable of triggering apoptotic and ultimately necrotic cell death upon perforin-assisted 
delivery to target cells (25). In addition to participating directly in the killing of target cells 
by the release of perforin and granzyme, NK cells also contribute to the global 
inflammatory response by releasing chemokines and cytokines such as IFNγ and tumour 
necrosis factor-alpha (TNFα), which will recruit and activate additional innate immune 
cells (26, 27). 
 Subsequent to kidney transplantation, many adaptive and innate immune cells 
infiltrate the graft and contribute to allograft injury. NK cells contribute to the innate 
immune response in the allograft and participate in IRI by lysing cells of the allograft using 
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perforin and granzyme in an antigen-independent manner, as well as by upregulating pro-
inflammatory cytokines (28, 29). NK cells are particularly interesting in a transplant setting 
because NK cells not only possess constitutive and potent cytotoxicity allowing them to 
kill target cells without pre-sensitization, but are also able to distinguish between allogeneic 
and self MHC antigens (30). Therefore, NK cells are capable of directly contributing to 
allograft loss via direct cytotoxicity, as well as indirectly exacerbating IRI by influencing 
the alloreactivity of T cells. 
 While the specific role of NK cells in renal IRI is poorly defined to date, Zhang et 
al. have demonstrated that NK cells play an important role in both acute and chronic kidney 
allograft injury (28, 31). NK cells are shown to be capable of directly killing TECs 
following renal IRI, and adoptive transfer of NK cells into mice lacking all lymphoid 
immune cells increased the severity of injury following IRI (28). These and other data 
demonstrate clearly that NK cells worsen the injury during IRI, independent of the adaptive 
immune system that is targeted by conventional immunosuppressants. This finding was 
also supported by more recent studies in mouse models (32-35) as well as in human studies 
(36, 37) 
Furthermore, a recent study that makes use of a B and T cell deficient Rag-/- 
transplantation model shows that NK cells induce chronic kidney injury and that depletion 
of NK cells ameliorated long term kidney injury (6), demonstrating that NK cells can 
directly react to donor allografts independent of B cell and T cell tolerance. Lastly, current 
immunosuppression therapies used in renal transplantation do not target NK cells directly 
(38). It may therefore be prudent to gain a better understanding into the role of NK cells in 
renal IRI in order to design immunosuppressive therapies that directly address NK cells to 
limit the damage caused by them in the allograft. 
1.4 Endothelium and IRI 
MVECs are the cells that comprise the inner-most layer of blood vessels and as 
such they are a particularly important cell type due to their critical role in maintaining 
vascular homeostasis (39). MVECs are critical regulators of smooth muscle contractions, 
are directly responsible for the exchange of macromolecules and fluids between the blood 
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and surrounding tissues, and also participate in immune surveillance (39). MVECs are 
particularly interesting in a transplant setting as they are the primary barrier between graft 
and host following any solid organ transplant. In fact, MVEC activation during 
transplantation has been shown to be an important factor and can result from IRI (40, 41). 
Activated MVECs mediate graft injury via increased vascular permeability, platelet 
adhesion, the expression of adhesion molecules, and through the release of pro-
inflammatory molecules such as interleukin 1 (IL-1) and TNFα (42). Cumulatively, the 
activation of MVECs leads to increased host immune infiltration and accelerated graft 
rejection (42).  
MVECs are also capable of inducing the activation and proliferation of T cells 
through the expression of active costimulatory molecules, including CD40 (43). T cell 
activation by CD40 results in the production of IFN-, which induces the expression of 
HLA class-II molecules on MVECs, leading to a sustained alloimmune reaction (44). 
Furthermore, the expression of P- and E-selectins, vascular cell adhesion molecule-1 
(VCAM-1), and intracellular adhesion molecule-1 (ICAM-1) by MVECs has been shown 
to correlate with graft damage and rejection (45), as these molecules allow for host 
leukocyte infiltration of the graft (46). As the primary biological barrier between graft and 
host, and as an activator of leukocytes, MVECs play a critical role in the alloimmune 
responses that follow any solid organ transplant.  
1.5 Programmed Cell Death in IRI 
IRI ultimately causes cells of the kidney allograft to undergo various different 
forms of programmed cell death, all of which contribute to the graft being damaged. These 
cell death pathways include caspase-dependent extrinsic apoptosis (47), intrinsic apoptosis 
(48, 49) and programmed necrosis, including necroptosis (50, 51) as well as pyroptosis (52, 
53) and ferroptosis (54). As these programmed cell death pathways are a major cause of 
cell death during IRI, a thorough understanding of the mechanisms and consequences of 
these cell death pathways is crucial.  
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1.5.1 Caspase-8-dependent Extrinsic Apoptosis in Renal IRI 
Apoptosis is a well-studied cellular process that is required for the non-pathological 
remodelling and repair of tissues and organs. In fact, apoptosis is the predominant form of 
cell death in a healthy kidney, with metabolically active TECs and MVECs undergoing 
particularly rapid turnover (55). However, under the setting of severe renal IRI it is possible 
for apoptosis of cells of the graft to exceed the regenerative capacity of the kidney, this will 
intuitively lead to loss of graft function and ultimately will lead to graft failure (56).  
 Within the inflammatory environment of IRI, cytokines such as TNFα and Fas 
ligand (FASL) (56, 57), as well as signalling molecules such as nitric oxide (58), will 
lead to the activation of caspase-8, a cysteine-aspartic acid protease that is responsible for 
extrinsic (aka death receptor-mediated) apoptosis. The initiation of extrinsic apoptosis is 
similar to the initiation of necroptosis, in which Complex I assembly leads to the poly-
ubiquination of receptor interacting protein kinase (RIPK)1, which leads to the formation 
of Complex II. The recruitment of caspase-8 to Complex II is where necroptosis and 
extrinsic apoptosis diverge. In extrinsic apoptosis, activated caspase-8 will cleave both 
RIPK1 and RIPK3, thereby eliminating the possibility of the necroptosis pathway and 
committing the cell towards extrinsic apoptosis (59). In addition to inactivating RIPK1 
and RIPK3, caspase-8 will also cleave downstream effector caspases into their activated 
forms (60). These activated ‘executioner’ caspases then proceed to dismantle the cell 
from the inside: DNA is fragmented, chromatin is condensed, and the characteristic 
membrane blebbing of apoptosis follows (61). Since caspase-8 promotes apoptosis in 
cells of the kidney allograft, and therefore graft damage during IRI, it would be of benefit 
to define strategies to inhibit caspase-8 activity in donor kidneys (62). However, 
apoptosis is an essential cell death pathway in a healthy organ, as is evidenced by the fact 
that caspase-8 knockout mice are embryonically lethal (63). Therefore, attempts to 
minimize apoptosis by interfering with caspase-8 activity must be confined to short 




Figure 2. Mechanism of extrinsic apoptosis. 
Upon TNFα binding to its receptor, TNFR-1, assembly of Complex I at the cytosolic tail 
domain of TNFR-1 occurs. Complex I consists of TRADD, cIAPs, TRAF2/5, and poly-
ubiquitinated RIPK1. Removal of the ubiquitin tail from RIPK1 by A-20 allows for the 
formation of DISC/Complex II from Complex I. The DISC complex then directly cleaves 
and activates pro-caspase-8, which cleaves and activates pro-caspases-3, -6, and -7, known 





1.5.2 Intrinsic Apoptosis in Renal IRI 
Another form of regulated cell death that is prominent during renal IRI is intrinsic 
apoptosis. During renal IRI, cells of the allograft experience a variety of stressful stimuli, 
including acidic pH (64) and intracellular ROS production (65). Under such stress, cells of 
the kidney allograft will start to upregulate the expression of B cell lymphoma-2 (BCL-2) 
family members, including the pro-apoptotic effector BCL-2 associated X protein (BAX) 
(66), which increases most dramatically of all family members, and remains increased as 
long as 7 days after transplant (67).  
 Stressful stimuli cause BAX to become activated and translocate to organelle 
membranes to promote apoptosis (68), the most important of which is the mitochondrial 
outer membrane (MOM) (69). At the MOM, BAX causes the opening of voltage-dependant 
anion channel-1 (VDAC-1) (70), which becomes associated with cyclophilin D (CypD) 
and adenine nucleotide translocator (ANT) to form the mitochondrial permeability 
transition pore (MPTP) (71, 72). The formation of the MPTP complex leads to the loss of 
mitochondrial membrane potential, which leads to swelling, mitochondrial inner 
membrane permeability, and subsequent rupture of the MOM (73). The rupture of the 
MOM is known as the ‘point of no return’ of intrinsic apoptosis, as it results in the release 
of massive amounts of cytochrome C (74) which binds to apoptotic protease activating 
factor 1 (APAF-1) to form the apoptosome complex (75). The assembly of the apoptosome 
complex will cause the activation of caspase-9 (76), which is responsible for cleavage and 
activation of downstream executioner caspases-3, -6, and -7 (77). The activated 
executioner caspases lead to the fragmentation of DNA and the degradation of many key 
cellular proteins (61), ultimately leading to cell death.  
 Intrinsic apoptosis of cells in the kidney allograft is very well studied, with a 
considerable amount of evidence pointing to the involvement of intrinsic apoptosis of 
graft cells in exacerbating renal IRI and kidney graft damage (78). Therefore, much like 
extrinsic apoptosis, strategies to transiently limit intrinsic apoptosis would confer survival 




Figure 3. Mechanism of intrinsic apoptosis. 
Stressful stimuli, such as an accumulation of ROS that occurs during IRI result in the 
activation of BAX. Activated BAX will then translocate to the MOM and become 
associated with VDAC-1, which then recruits ANT and CypD to form the MPTP. The 
formation of the MPTP leads to cytochrome C release which binds to APAF-1 to form the 
apoptosome complex. The apoptosome complex activates caspase-9 which cleaves and 
activates executioner caspases-3, -6, and -7. The activated executioner caspases lead to 









1.5.3 Receptor Interacting Protein Kinase 3 (RIPK3)-mediated 
Necroptosis in Renal IRI 
Necroptosis is a regulated form of necrosis that occurs in kidney allografts. Recent 
data implicates necroptosis as a major factor contributing to cell death in kidney allografts 
and in the worsening of IRI (79).  Necroptosis is not distinguishable from necrosis 
biochemically or morphologically (80, 81), as both of these cell death pathways involve 
the swelling of the mitochondria and the cytoplasm, both due to ATP depletion, as well as 
loss of plasma membrane integrity, and eventual cell lysis (82, 83). Necroptosis is similar 
to apoptosis in that it is programmed, but necroptosis also resembles necrosis generally in 
that cell lysis and the leakage of intracellular immunogenic DAMPs occurs (84).  
Necroptosis in kidney allografts can be triggered by many different ways, and 
typically involves specific death receptors binding to their ligands. Death receptors that 
trigger necroptosis upon ligand binding include: TNF receptor 1 (85), FAS receptor (86), 
TNF-related apoptosis inducing ligand receptor (87, 88) and TLR-4 (89). All of these 
receptors can trigger necroptosis upon ligand binding via different downstream pathways 
(90, 91). A commonality between necroptotic pathways is the activation of receptor 
interacting protein kinase 1 (RIPK1) and RIPK3, which are serine/threonine kinases that 
form into a necrosome complex (92-94). Upon ligand binding to its corresponding death 
receptor, several different adaptor proteins (95) are recruited to the cytoplasmic domain of 
the activated death receptor, including poly-ubiquinated RIPK1 (96), which together with 
the death receptor form necrosome Complex 1 (97). After initiation of complex 1, the 
ubiquitin tail of RIPK1 is cleaved by enzymatic effectors of necroptosis such as A20 (98) 
or cyclindromatosis (99, 100). The cleavage of RIPK1’s ubiquitin tail leads to the 
formation of Complex II from Complex I, which includes both RIPK1 and RIPK3 (80, 
101). After the formation of necrosome Complex II, RIPK3 will phosphorylate and activate 
downstream molecules, including mixed lineage kinase domain-like (MLKL) (102). 
Phosphorylated-MLKL will then cause pore formation in the plasma membrane, leading 
to cell lysis and the release of DAMPs from the cell (103). This resultant release of 
intracellular immunogenic DAMPs will recruit other cytotoxic immune cells, including 
NK cells (20). The release of DAMPs and recruitment of immune cells that occurs during 
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IRI highlights the fact that necroptosis is problematic in a transplant setting. IRI causes 
death of allograft cells which leads to DAMP release, which leads to the recruitment of 
additional immune cells, which contribute to further injury in an auto-amplification 
fashion. For this reason, limiting or controlling the release of DAMPs during IRI, or 
preventing the released DAMPs from recruiting cytotoxic immune cells, may prove to be 
an effective strategy to attenuate damage caused during IRI. One DAMP that is particularly 
interesting and is receiving much attention recently in transplant, is cell-free DNA 







Figure 4. Mechanism of necroptosis. 
Upon TNFα binding to its receptor, TNF-R1, assembly of Complex I at the cytosolic tail 
domain of TNF-R1 occurs. Complex I consists of TRADD, cIAPs, TRAF2/5, and poly-
ubiquitinated RIPK1. Removal of the ubiquitin tail from RIPK1 by A-20 allows for the 
formation of the DISC/Complex II from Complex I. In the absence of caspase-8 activation, 
RIPK1 and RIPK3 become associated and form the Necrosome Complex. Once the 
Necrosome Complex is formed, RIPK3 phosphorylates MLKL. Phosphorylated MLKL 




1.6 Cell-free DNA in Transplantation 
As the name suggests, cfDNA are degraded fragments of DNA that have been 
released into the bloodstream and circulate extracellularly. Circulating nucleic acids were 
first discovered in 1948 (104), and in 1966 it was shown for the first time that cfDNA levels 
are higher in diseased patients compared to healthy individuals, a discovery that was made 
first in Lupus patients (105). Since its discovery, cfDNA has become a useful diagnostic 
tool, particularly in diagnosing pre-eclampsia (106), fetal chromosome abnormalities 
(106), and various forms of cancer (107). In fact, the ability to detect circulating tumor 
DNA led to the development of the ‘liquid biopsy’, allowing for non-invasive diagnosis 
and screening of various cancers (108). As research progresses, it has become evident that 
cfDNA is not just a biomarker for a few specific diseases, but rather it is a marker of general 
cellular injury. This position is supported by the recent finding that cfDNA levels become 
measurably higher with age (109). 
 The current gold standard for monitoring graft function in kidney transplant 
recipients is the serial measurement of serum creatinine levels (110). Unfortunately, a 
deterioration in graft function can only be detected after significant damage to the graft has 
occurred (111). As such, a more sensitive biomarker of kidney graft function is needed. 
Furthermore, subclinical rejection (graft damage in the absence of a measurable increase 
in serum creatinine) can be detected only at present by surveillance biopsies which are 
costly and invasive (112). As such, a less invasive and more efficient detection of 
subclinical rejection is needed. A potential solution to this problem is donor-derived cell-
free DNA (ddcfDNA). ddcfDNA is detectable in both the blood and urine of transplant 
recipients (113) and is a direct result of damage to the graft (114). For these reasons, 
ddcfDNA is a potential biomarker of graft injury. The potential to isolate and quantify 
ddcfDNA from urine or serum may lead to new, less-invasive diagnoses of acute rejection 
and graft damage. Indeed, high levels of ddcfDNA post-transplantation have been reported 
and may be caused by unbalanced programmed cell death during IRI (115-117). 
 Despite the aforementioned intrigue, little is known about the mechanism of cfDNA 
release from the graft. Apoptosis (118-121), necrosis (121) and active secretion (122-124) 
have all been postulated as mechanisms of cfDNA release into the blood. Furthermore, 
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even less is known of the biological function of cfDNA. Most of the research on cfDNA is 
as a potential biomarker for injury. However, it has also been shown that cfDNA is more 
GC-rich than genomic DNA (125) and that cfDNA is capable of binding TLR9, leading to 
the activation of the NF-kB pathway and the secretion of TNFα and Interleukin-10 (IL-10) 
in human adipose-derived mesenchymal stem cells (haMSCs) (126). Clearly cfDNA is not 
just a biomarker for cellular injury, but is also a biologically active molecule that is capable 
or participating in and influencing immune responses. Greater insights on the release and 
mechanism of action of cfDNA in transplant may alter diagnosis of early injury as well as 
potentially direct new therapies. 
1.7 Hypothesis 
We hypothesize that cfDNA is released by MVECs during programmed cell death 
with ischemia reperfusion injury, and that cfDNA acts as both a biomarker for cellular 
injury as well as a biologically active molecule capable of amplifying inflammation and 
organ injury. 
1.8 Objectives 
Our first objective is to determine if MVECs release cfDNA during programmed 
forms of cell death. Our second objective is to determine if cfDNA is released during 
ischemia reperfusion injury in vivo, and whether it can be prevented with cell death 
inhibition. Our third and final objective is to determine if cfDNA is capable of activating 










2 MATERIALS AND METHODS 
 
2.1 Animals 
Wild-type C57BL/6 (B6) mice were obtained commercially from Charles River Canada 
Inc (St. Constant, QC). B6 RIPK3-/- mice were generously provided by Dr. Kim Newton 
(Genentech) (127). Combined B6 RIPK3-/- Caspase-8-/- double knockout (DKO) mice were 
generously provided by Dr. Douglas Green (St. Jude Children’s Research Hospital, TN) 
(128). All mice were maintained in the animal care facility at Western University using 
approved protocols. All experimental procedures were approved by the Animal Care 
Committee at Western University.    
2.2 Microvascular Endothelial Cell (MVEC) Culture 
Microvascular endothelial cells (MVECs) were isolated from mice hearts as previously 
described (129). MVECs were grown in DMEM (Invitrogen), supplemented with 10% fetal 
bovine serum, 2mM L-glutamine, 100IU/mL penicillin, and 100IU/mL streptomycin 
(Invitrogen). 
2.3 NK Cell Culture 
Murine NK cells were purified from the spleens of WT C57BL/6 mice. Adult mice were 
sacrificed and spleens were removed and mechanically processed through a 20µm cell 
strainer (BD Biosciences, Mississauga, ON). Following mechanical processing, whole 
splenocytes were labelled with anti-CD3ε magnetic MACS beads (Miltenyi Biotec, 
Auburn, CA) for 10 minutes at 4°C in 500μL of MACS buffer (PBS, 1% FBS, 0.5% 
EDTA). Labelled splenocytes were then passed through a magnetic MACS bead column 
to deplete all CD3ε+ cells. Subsequently, the column was washed three times with MACS 
Buffer. Lastly, NK cells were purified from the column flow through by CD49b+ selection 
on MACS beads columns using anti-CD49b magnetic MACS beads (Miltenyi). NK cells 
were cultured in RPMI media (Invitrogen), supplemented with human IL-2, 2mM 
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glutamine, 1mM sodium pyruvate, 10mM HEPES, 0.5mM 2-ME, 100µg/mL streptomycin, 
100 IU/mL penicillin and 10% FBS. NK cell purity was confirmed to be >93% 
CD49b+NK1.1+, CD3- by flow cytometry. 
2.4 B16-Bims and B16-FADD-DD Cell Culture 
B16-Bims and B16-FADD-DD cell cultures were generously provided by Dr. Lakshman 
Gunaratnam (Western University, London, ON). B16-Bims and B16-FADD-DD cell lines 
are derived from mouse melanoma cell line B16 as described (130), resulting in cell lines 
with tetracycline/doxycycline-inducible expression of either Bcl-2 family protein Bims or 
Fas-associated death domain protein (FADD). The induced expression of Bims results in 
rapid apoptosis (130), while the induced expression of FADD death domain (FADD-DD) 
results in nonapoptotic/necrotic cell death. Both cell lines were cultured in DMEM 
(Invitrogen) supplemented with 10% FBS, 50µg/µL penicillin/streptomycin, 50µM 2-ME 
and 50µg/mL G-418 sulfate. Gene expression was induced by stimulating cells with 
1µg/mL tetracycline. 
2.5 Cell Death Assay 
B6 MVECs were seeded on 6-well flat-bottomed plates for 24 hours in complete DMEM 
(Invitrogen) in order to generate a confluent mono-layer. Subsequently, MVECs were 
treated with human TNFα (100ng/mL, PeproTech, USA), Smac-mimetic (15nM, 
Selleckchem, USA), Z-Ile-Glu-Thr-Asp-Fluoromethylketone (IETD, 30µM, APExBIO, 
USA), and Necrostatin-1 (Nec-1, 10µM, Merck Millipore, USA) in serum free media for 
24 hours. TNFα is an inflammatory cytokine that induces cell death. Smac-mimetic 
suppresses the function of Inhibitor of Apoptosis Proteins (IAPs) which leads to caspase 
activation, promoting apoptotic cell death. IETD inhibits caspase-mediated apoptosis by 
inhibiting caspase-8. Nec-1 is a RIPK1 inhibitor that results in inhibited necroptosis. Cell 
death was quantified using SYTOX® Green Nucleic Acid Stain (100nM, ThermoFisher, 
USA), in which cell death is correlated to fluorescence intensity of SYTOX. Fluorescent 
intensity of SYTOX was monitored using the IncuCyte ZOOM® System (Essen 
Bioscience, USA). Cell death was also quantified using flow cytometry. Briefly, cells were 
trypsinized (Gibco) 24 hours after treatment with the same reagents mentioned above, and 
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washed with PBS. Cell death was detected with propidium iodide (PI, BD Bioscience) and 
Annexin-V (BD Bioscience) staining and analyzed with the CytoFLEX flow cytometer 
(Beckman Coulter, USA).  
2.6 cfDNA Isolation 
cfDNA was extracted from either serum or cell culture supernatant using the NucleoSpin 
Gel and Polymerase Chain Reaction (PCR) Clean-up kit (Machery-Nagel), following the 
PCR clean-up protocol with minor adjustments. The PCR clean-up protocol is a 
particularly suitable method for cfDNA isolation as it avoids the use of both membrane 
lysis and protein degradation steps that may liberate cellular genomic DNA from live cells 
or DNA bound to blood proteins in the serum. Prior to cfDNA extraction, samples were 
centrifuged at 16000 x g for 5 minutes at room temperature in order to remove any live 
cells from the cell culture supernatant or serum. After centrifugation and prior to extraction, 
samples were kept at -80 °C. For each biological replicate, cfDNA was extracted from 
either 1.0mL of cell culture supernatant, or from 100µL of serum. Prior to extraction, 
samples were mixed with NTB binding buffer in a buffer-to-sample ratio of 2:1. Next, the 
samples were vortexed and added to the spin column and centrifuged at 11000 x g for 1 
minute at room temperature. The columns were washed twice and dried twice, and cfDNA 
was eluted into 20µL of elution buffer.    
2.7 cfDNA Quantification 
cfDNA was quantified using the Qubit® 1.0 fluorometer (Invitrogen) in combination with 
the Quant-iTTM PicoGreenTM dsDNA Assay Kit (Invitrogen) according to the 
manufacturer’s instructions. Briefly, 1µL of extracted cfDNA was diluted in 9µL of DEPC 
H2O and then mixed with 90µL of PicoGreenTM working solution (200:1 mixture of TE 
buffer and Quant-iTTM PicoGreenTM reagent). Samples were quantified in triplicate 
(100µL/well) in 96-well plates. cfDNA concentration was calculated using a standard 
curve ranging from 0 to 100ng/µL, according to the manufacturer’s protocol using Lambda 
DNA provided with the PicoGreenTM kit. Samples were excited at 480nm and fluorescence 
emission intensity was detected at 520nm.  
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2.8 Kidney Ischemia Reperfusion Injury (IRI) Model  
The left kidney was removed and a renal clamp was applied to the right kidney pedicle of 
wild type B6, RIPK3-/-, or RIPK3-/-/caspase-8 double knockout (DKO) mice for 45 minutes 
(28). Body temperature during surgery was not precisely regulated, relying on a heat-cool 
blanket with average body temperatures during surgery being approximately 34°C, 
measured using a rectal thermometer, or was precisely controlled at either 24°C, 28°C, 
32°C, or 36°C using the Homeothermic Monitoring System (Harvard Apparatus). Serum 
was collected at either 24- or 48-hours post-surgery. Serum creatinine levels were 
determined using the Catalyst Dx Chemistry Analyzer (IDEXX, Canada). 
2.9 Real-Time Quantitative Polymerase Chain Reaction 
Total RNA was extracted from NK cells using the RNeasy Mini kit (Qiagen, USA). The 
concentration and purity of isolated RNA was measured using the GENESYSTM UV-vis 
spectrophotometer (Thermofisher, Canada) in order to accurately generate standardized 
quantities of cDNA. cDNA generation from RNA was accomplished using Superscript II 
Reverse Transcriptase (Thermofisher, USA). Real-time quantitative PCR was performed 
using the Brilliant SYBR Green qPCR Master MixTM kit (ABM, Canada) with the CFX 
Connect (BioRad, USA) qPCR machine. Normalized delta threshold cycle (Ct) value and 
relative expression levels (ΔΔCt) were calculated according to the manufacturer’s protocol. 
Primers used are: β-actin F (CCA GCC TTC CTT CCT GGG TA), β-actin R (CTA GAA 
CAT TTG CGG TGCA), Granzyme B F (TGG GGG ACC CAG AGA TTA AAA), 
Granzyme B R (TTT CGT CCA TAG GAG ACA ATG C), IFNγ F (TGC ATC TTG GCT 
TTG CAG CTC), IFNγ R (GGC TTT CAA TGA GTG TGC CGT), TNFα F (GCC TCT 
TCT CAT TCC TGC TTG), and TNFα R (CTG ATG AGA GGG AGG CCA TT). 
2.10 Statistical Analysis 
Experimental values were expressed as mean + SD. Data was analyzed using 1-Way 
ANOVA with Tukey’s Multiple Comparison test. All statistical analyses were performed 







3.1 MVECs Undergo Apoptosis and Necroptosis when 
Treated with Various Inflammatory Cytokines in vitro 
In order to first characterize the programmed cell death of wild type B6 MVECs, 
we added various inflammatory cytokines to MVEC cultures. Mouse TNFα, Smac-
mimetic, caspase-8 inhibitor IETD, and the RIPK1-inhibitor Nec-1 were added to wild type 
B6 MVEC cell cultures. Cell death was quantified by SYTOX fluorescent intensity with 
IncuCyte ZOOM live imaging system. Treatment of MVECs with TNFα alone did not 
increase cell death compared to untreated cells. The addition of Smac-mimetic, an inhibitor 
of inhibitor of apoptosis proteins (IAPs), enhanced TNFα-induced cell death, suggesting 
apoptotic cell death (Figure 5A). The addition of caspase-8 inhibitor IETD further 
enhanced TNFα-induced cell death. Since caspase-8 is required for apoptotic cell death, it 
is likely that the cell death observed with IETD treatment is not from apoptosis. Lastly, 
when necroptosis was inhibited in TNFα, Smac-mimetic, and IETD-treated MVECs using 
the RIPK1 inhibitor Nec-1, cell death was eliminated to near-baseline levels (Figure 5A). 
As RIPK1 is essential in necroptosis, the reduction in cell death with RIPK1 inhibition is 
indicative that TNFα, Smac-mimetic, and IETD-treated MVECs are undergoing 
necroptosis. To confirm this, treated cells were also stained with Annexin V and PI and 
were analyzed by flow cytometry. Annexin V positive staining supports apoptosis as the 
primary form of cell death, PI positive staining indicates necrosis, and double positive cells 
indicate late apoptosis and early necroptosis. Indeed, MVECs treated with TNFα and Smac-
mimetic show a cell population that is Annexin V positive, with no cell populations that 
are PI positive, supporting mostly apoptotic cell death (Figure 5B). Furthermore, MVECs 
treated with TNFα, Smac-mimetic, and caspase-8 inhibitor IETD show a large portion of 
cells that are Annexin V and PI double positive, while the addition of Nec-1 eliminates this 
cell population, suggesting as expected, that necroptotic cell death is occurring in cells 














Figure 5. Treatment of MVECs with various cytokines results in apoptosis and 
necroptosis. 
(A) B6 MVEC were plated on 6 well plates in triplicates and were treated with 100ng/mL 
human TNFα (T), 15nM Smac-mimetic (S), 30µM IETD (I) and 10µM Nec-1 (N) along 
with the addition 100nM SYTOX green. Cell death was quantified by SYTOX fluorescent 
intensity as measured by the IncuCyte ZOOM live imaging system. Data at 24 hours were 
shown as mean +SD of 6 independent experiments. ***p ≤0.0001, 1way ANOVA with 
Tukey’s Multiple Comparison Test. (B) B6 MVEC were plated on 6 well plates in 
triplicates and were treated with 100ng/mL human TNFα, 15nM Smac-mimetic, 30µM 
IETD and 10µM Nec-1 for 24 hours and cell death was characterized using Annexin V and 
PI staining, followed by flow cytometry analysis. Data shown are representative of at least 
3 independent experiments. 
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3.2 cfDNA is Released by MVECs During Apoptosis and 
Necroptosis in vitro 
Next, we sought to investigate whether cfDNA is released from MVECs during 
cytokine-induced cell death. MVECs were treated with cytokines as described in Figure 5. 
cfDNA was isolated from the supernatant of cytokine-treated MVEC cell culture and was 
quantified using a PicoGreenTM assay.  
 It has been suggested that cfDNA is released from apoptotic cells (118-121), 
necrotic cells (121), as well as by active secretion (122-114). In agreement, our data 
indicate that cfDNA indeed is released in significantly large quantities by apoptotic (TNFα 
and Smac-mimetic treated) cells when compared to untreated cells (Figure 6). However, 
our data shows that cfDNA is released in large quantities by necroptotic (TNFα, Smac-
mimetic, and IETD treated) cells when compared to untreated cells, and that necroptotic 
cells release more cfDNA than apoptotic cells (Figure 6). Furthermore, when both 
necroptosis and apoptosis are inhibited (via treatment with Nec-1 and IETD, respectively) 




Figure 6. cfDNA is released by MVECs during apoptosis and necroptosis in vitro. 
B6 MVECs were plated on 6 well plates in triplicates and were treated with 100ng/mL 
human TNFα (T), 15nM Smac-mimetic (S), 30µM IETD (I) and 10µM Nec-1 (N). cfDNA 
was isolated from the supernatant of treated cells and was quantified using the PicoGreenTM 
assay. Data is shown as Mean +SD of 8 independent experiments. ***p<0.0001, One-Way 






3.3 cfDNA Release is Regulated by Cell Death Programs 
During Ischemia Reperfusion Injury in vivo 
To investigate whether cfDNA is released during kidney IRI, a mouse model of 
kidney IRI was employed. The left kidney was removed and a renal clamp was applied to 
the right kidney pedicle of wild type B6, RIPK3-/-, or RIPK3/caspase-8 double knockout 
(DKO) mice and was removed after 45 minutes. A wild type B6 sham surgery, in which 
the mouse was anesthetized, surgically incised, but without renal clamping, was used as a 
control. Body temperature during surgery was not precisely regulated; however, a rectal 
probe was used at multiple intervals during the surgery in order to determine body 
temperature in the absence of precise regulation. Rectal probe measurements indicated an 
average body temperature of 34°C during the procedure when body temperature is not 
precisely regulated. Serum was collected at 48-hours post-surgery. Serum creatinine was 
measured using the Catalyst Dx Chemistry Analyzer (IDEXX). cfDNA was isolated from 
serum and quantified exactly as described in the isolation of cfDNA from cell culture 
supernatant in Figure 6. 
 Our results indicate that serum cfDNA is significantly elevated 48 hours post-IRI 
in both wild type B6 and RIPK3-/- mice when compared to the sham surgery, and that 
RIPK3 deficiency modestly reduced serum cfDNA levels post-IRI (Figure 7A). 
Furthermore, DKO mice show no measurable difference in serum cfDNA 48 hours post-
IRI when compared to the sham surgery (Figure 7A). Serum cfDNA levels in DKO mice 
48 hours post-IRI are significantly lower than serum cfDNA levels in both B6 and     
RIPK3-/- mice 48 hours post-IRI. 
 Furthermore, serum creatinine levels were markedly higher in wild type B6 mice 
48 hours post-IRI when compared to the sham surgery (Figure 7B). Interestingly, both 
RIPK3-/- and DKO serum creatinine levels 48 hours post-IRI were not significantly 











Figure 7. cfDNA is released during IRI in vivo and is ameliorated in Caspase-
8/RIPK3 DKO mice.  
The left kidney was removed and a renal clamp was applied to the right kidney pedicle of 
wild type B6, RIPK3-/-, and RIPK3-/- Caspase-8-/- (DKO) mice for 45 minutes. Average 
body temperature during surgery was measured at 34°C. Serum was collected 48 hours 
post-IRI for creatinine and cfDNA quantification. A. cfDNA was isolated from serum 
and quantified exactly as described in the isolation of cfDNA from cell culture 
supernatant in Figure 6. Data is shown as Mean +SD of 6 independent experiments. 
***p<0.0001, **p<0.001, One-Way ANOVA with Tukey’s Multiple Comparison Test. 
B. Serum creatinine levels were measured using the Catalyst Dx Chemistry Analyzer 
(IDEXX). Data is shown as Mean +SD of 6 independent experiments. ***p<0.0001, 












3.4 cfDNA Release During Ischemia Reperfusion Injury in 
vivo is Correlated to the Degree of Injury 
Previous data have shown that kidney IRI in rodent models (131) and in humans 
(134) is temperature-sensitive and that lower temperatures inhibit kidney IRI. To 
investigate whether cfDNA release during kidney IRI is temperature-dependant, the same 
mouse model of kidney IRI as described in Figure 7 was employed, except that body 
temperature during the surgery was precisely controlled at either 24°C, 28°C, 32°C, or 
36°C using a sophisticated homeothermic monitoring system (Harvard Apparatus). Briefly, 
the left kidney was surgically removed and a renal clamp was applied to the right kidney 
pedicle of wild type B6 mice. Serum was collected at either 24- or 48-hours post-surgery. 
Serum creatinine was measured using the Catalyst Dx Chemistry Analyzer (IDEXX). 
cfDNA was isolated from serum and quantified exactly as described with isolation from 
cell culture supernatant in Figure 6.  
 Our data indicate that the body temperature at which surgery is performed is a 
crucial determinant of the degree of renal injury caused by IRI (Figure 8). Firstly, at an 
early time point of 24 hours post-IRI, cfDNA levels isolated from serum show an increase 
in a temperature/injury-dependant manner, with statistically significant increases in serum 
cfDNA occurring between 24°C and 28°C, 28°C and 32°C, as well as between 32°C and 
36°C (Figure 8A). Furthermore, at the same 24-hour time point, serum creatinine levels 
also increase in a temperature-dependant manner. Statistical differences between 24°C and 
28°C are observed, as well as between 28°C and 32°C (Figure 8B). Interestingly, no 
significant difference in serum creatinine levels was measured between 32°C and 36°C, 
nor was a significant increase detected when comparing IRI at 24°C with sham control 
(Figure 8B). It is worth noting that serum creatinine levels for both sham surgery and 24°C 
IRI were at or below the lower limit detectable using the IDEXX.  
 Our data show a similar, but less pronounced temperature-dependant increase in 
both serum cfDNA and creatinine levels when the serum is analyzed 48-hours post-IRI 
instead of 24-hours post-IRI (Figure 8C). Much like at 24-hours post-IRI, cfDNA levels 
isolated from serum following IRI is higher than sham control across all temperature 
groups (Figure 8C). An increase in serum cfDNA was detectable between 24°C and 32°C, 
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as well as between 24°C and 36°C, but not between 24°C and 28°C (Figure 8C), although 
a clear trend towards higher cfDNA at higher temperatures is observed.  
 Lastly, at 48-hours post-IRI, serum creatinine levels also increase in a 
temperature-dependant manner (Figure 8D). However, at 48-hours these differences are 
less pronounced than at 24-hours. 32°C and 36°C IRI are both statistically higher than 
sham control, with an appreciable difference measured between 32°C and 36°C (Figure 
8D). However, no significant increase in serum creatinine levels were detected when 
comparing 24°C and 28°C with sham control. Again, it is worth noting that serum 
creatinine levels collected 48-hours post-surgery for sham surgery, 24°C IRI, and 28°C 
IRI were at or below the lower limit detectable using the IDEXX. Taken together, our 




















Figure 8. cfDNA is released during IRI in vivo in a temperature-dependent manner. 
The left kidney was surgically removed and a renal clamp was applied to the right kidney 
pedicle of wild type B6 mice for 45 minutes. Body temperature during surgery was 
precisely controlled at either 24°C, 28°C, 32°C, or 36°C. Serum was collected either 24- 
or 48-hours post-IRI for creatinine and cfDNA quantification. A./C. cfDNA was isolated 
from serum and quantified exactly as described in Figure 6. B./D. Serum creatinine levels 
were measured using the Catalyst Dx Chemistry Analyzer (IDEXX). Data is shown as 
Mean +SD of 4 independent experiments. ***p<0.0001, **p<0.001, *p<0.01, One-Way 
ANOVA with Tukey’s Multiple Comparison Test. 
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3.5 cfDNA is Capable of Activating NK Cells in vitro 
Previous work from our group has established that NK cells are key regulators in 
cell death during IRI and it has been demonstrated that NK cells play a key role in both 
acute and chronic kidney allograft injury (28, 31-37). NK cells have been shown to 
participate directly in the killing of kidney TECs following renal IRI (28) and it is well-
established that NK cells induce cytotoxicity by releasing perforin and granzyme (25). 
Furthermore, NK cells also contribute to the global inflammatory response during IRI by 
releasing chemokines and cytokines such as IFNγ and TNFα which recruit and activate 
additional innate immune cells that contribute to and worsen the inflammatory landscape 
during IRI (26, 27). 
 Furthermore, previous work has established that cfDNA is capable of binding to 
TLR9, activating the NF-kB pathway, leading to the secretion of TNFα and IL-10 in 
haMSCs (126). These results clearly indicate that cfDNA may not just be a biomarker of 
cell death, but that it may also play a role in exacerbating inflammation, thereby worsening 
acute allograft injury. For these reasons, we sought to characterize the response of NK 
cells, known mediators of IRI, to cfDNA in vitro.  
 Firstly, primary NK cells were isolated and treated with cfDNA isolated from the 
serum of wild type B6 mice 48-hours post-IRI. We also sought to determine whether 
cfDNA from necrotic cells differed from cfDNA from apoptotic cells in its ability to 
activate NK cells. In order to accomplish this, we also subjected NK cell culture to 100 
ng/mL cfDNA isolated from programmed cell death control cell lines B16-BIMs cell 
culture and B16-FADD-DD cell culture, which are genetically capable of undergoing only 
apoptosis and necroptosis, respectively, in lieu of all other forms of programmed cell death. 
Positive controls, 50µg/mL PolyIC and 2000 IU/mL human IL-2 were also added to NK 
cell culture as these are well described activators of NK cells.  
 Granzyme B expression was significantly increased following treatment with 
100ng/mL cfDNA isolated from B6 IRI serum, B16-BIMs cells, and B16-FADD cells 
(Figure 9A). Importantly, no increase in Granzyme B expression was observed in NK cells 
treated with elution buffer, or with 100ng/mL cfDNA + DNase (Figure 9A). 
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Unsurprisingly, Granzyme B expression was significantly increased following treatment 
with positive controls PolyIC and human IL-2 (Figure 9A). 
 Similarly, IFNγ expression was also significantly increased following treatment 
with 100ng/mL cfDNA isolated from B6 IRI serum, B16-BIMs cells, and B16-FADD cells 
(Figure 9B). Again, no increase in IFNγ expression was observed in NK cells treated with 
elution buffer, or with 100ng/mL cfDNA + DNase (Figure 9B). Lastly, IFNγ expression 
was significantly increased following treatment with PolyIC, but no increase in expression 
was observed with human IL-2 treated cells (Figure 9B). 
Similar to Granzyme B and IFNγ, TNFα expression was significantly increased 
following treatment with 100ng/mL cfDNA isolated from B6 IRI serum and B16-BIMs 
cells (Figure 9C). However, although a clear trend is observable, statistically significant 
increases in TNFα expression were not observed in NK cells treated with 100ng/mL 
cfDNA isolated from B16-FADD cells (Figure 9C). Visually, it is clear that there is a trend 
towards upregulation, however, since TNFα expression is only modestly increased even in 
the highest groups (approximately 2-fold in PolyIC positive control), it is likely that a very 
high n value would be required for statistical significance. Importantly, no increase in 
TNFα expression was observed in NK cells treated with elution buffer, or with 100ng/mL 
cfDNA + DNase (Figure 9C). Lastly, much like IFNγ, TNFα expression was significantly 























Figure 9. cfDNA is capable of activating NK cells in vitro. 
NK cells were purified from the spleen of wild type B6 mice and were treated in vitro for 
12 hours with elution buffer from which cfDNA is isolated as a negative control, as well 
as with 50 and 100ng/mL cfDNA isolated from the serum of B6 mice following IRI. NK 
cells were also treated with 100ng/mL cfDNA isolated from B16-BIMs and B16-FADD 
cells, which are genetically capable of only undergoing only apoptosis and necrosis, 
respectively. Lastly, NK cells were treated with 50µg/mL PolyIC and 2000 IU/mL human 
IL-2, two known activators of NK cells, as positive controls. RNA was isolated from 
cultured cells 12 hours after treatment and cDNA was generated. Relative fold change of 
Granzyme B (A), IFNγ (B), and TNFα (C) mRNA expression before and after treatment 
was determined by qPCR. Data is shown as Mean +SD of 4 independent experiments. 







4.1 cfDNA is Released During Apoptosis and Necroptosis in 
vitro 
For our interest in transplants, the foremost requirement for a biomarker that is to 
be used for cellular injury is that it correlates positively with cell injury or death. That is to 
say that when cell death increases, the marker should increase, and when cell death 
decreases, the marker should also decrease. Our data strongly support that cfDNA release 
in vitro is correlated with established measures of cell death, such as SYTOX fluorescence 
intensity and staining with PI and Annexin V. MVECs treated with TNFα and Smac-
mimetic to induce apoptosis showed a substantial increase in cell death as measured by 
SYTOX intensity, and similarly showed a substantial increase in cfDNA release. 
Furthermore, MVECs treated with TNFα, Smac-mimetic, and IETD to induce necroptosis 
also showed a substantial increase in cell death compared to untreated controls, and 
similarly showed an increase in cfDNA release as well. Importantly, MVECs treated with 
TNFα, Smac-mimetic, IETD, and Nec-1, a treatment regimen that inhibits both apoptosis 
and necroptosis, showed a substantial reduction in both cell death and cfDNA release. From 
our data, it is evident that cfDNA release mirrors traditional cell death measures and thus 
may be a potential biomarker of cellular injury that is useful in diverse forms of organ 
injury in transplantation. 
 Another objective was to establish whether apoptosis or necroptosis differ in their 
release of cfDNA, as cell death during organ injury may be polarized to one form or 
another. Additionally, defining the pathways involved would be critical to selection of 
pharmacologic inhibitors of specific forms of cell death. It has been previously postulated 
that both apoptosis and necroptosis may contribute to cfDNA release (118-121) but this 
has not been determined conclusively to date. Our data clearly indicate that necroptotic 
MVECs (TSI treated) released considerably more cfDNA than apoptotic MVECs (TS 
treated). Briefly, we are confident that TS treated cells undergo apoptosis for the following 
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reasons. Firstly, TNFα is a known inducer of apoptosis. MVECs, as endothelial cells, are 
particularly hardy cells that are resistant to programmed cell death. As such, in our model, 
in order to induce significant levels of apoptosis, cells are also treated with Smac-mimetic. 
Smac-mimetic suppresses the function of IAPs, and this leads to caspase activation and the 
inhibition of RIPK1 polyubiquination, thereby promoting cell death. This is confirmed by 
the fact that TS treated cells show a population of Annexin V positive cells, with no 
population of PI positive cells. Although there is overlap, it is generally accepted that 
Annexin V primarily labels early apoptotic cells while PI labels necrotic or late-apoptotic 
cells. Therefore, we are confident that TS treated cells are primarily undergoing apoptosis. 
The addition of IETD to TS treated cells inhibits caspase-8, a key molecular effector of 
apoptosis. When caspase-8 is inhibited, cells can’t undergo apoptosis and as a result the 
cell is programmed to shift to necroptosis (132). In fact, necroptosis has been postulated as 
a ‘failsafe’ evolutionary response to infections from caspase-8 inhibiting viruses (133). 
This is reflected in the fact that TSI treated cells show a significant population that are PI 
and Annexin V double positive, an indicator of necroptosis. Furthermore, the addition of 
Nec-1 inhibited necroptosis and cfDNA release. In conclusion, necroptotic MVECs 
released significantly more cfDNA than apoptotic MVECs.  
It was not determined by our studies whether cfDNA from apoptotic cells is 
different than cfDNA from necroptotic cells in sequence, size, or biological effect. It is 
well accepted that while necrosis promotes inflammation (84), apoptosis is relatively 
‘silent’ in its effect on immune cells and can contribute to immune tolerance (61). Further 
studies on cfDNA sequence and packaging within lipid bound vesicles may identify such 
a difference. During IRI, cells dying by apoptosis will fragment organelles and DNA, 
which are packaged into exosomes in a controlled manner along with other DAMPs and 
cellular materials (61). The resultant exosomes are non-immunogenic as their contents are 
encased in exosomes and kept secluded from the immune system. In contrast, cells dying 
by necroptosis experience cell lysis and the leakage of intracellular DAMPs (84) which are 
detected by resident dendritic cells (17) and results in the recruitment of additional immune 
cells, including T cells (20), B cells, macrophages, neutrophils, and NK cells (21). Due to 
the release of DAMPs and the recruitment of immune cells, necroptosis promotes 
inflammation (84). In the setting of IRI, perhaps cfDNA released from apoptotic cells is 
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encased in membrane-bound exosomes, while cfDNA released from necroptotic cells is 
not. This distinction would explain why apoptosis is non-inflammatory and necroptosis is 
pro-inflammatory. Although our data show no biological difference between apoptotic and 
necroptotic cfDNA, perhaps our method of cfDNA extraction is disrupting the exosomes 
that are produced by apoptotic cells. Further studies on the presence and contents of these 
exosomes in both serum and cell culture supernatant following apoptosis, necroptosis, or 
IRI, may clarify this.  
4.2 cfDNA is a Sensitive Biomarker for Kidney Injury 
  Shortly following organ transplantation, donor-derived cfDNA can be detected in 
the blood or urine of the recipient (113). As such, cfDNA is increasingly being viewed as 
a potential way to detect allograft injury in clinical transplantation, particularly with 
rejection (114). In contrast to apoptosis, there is currently no information regarding the role 
of necroptosis in generating cfDNA during organ injury and transplantation. Our next step 
in determining the potential of cfDNA as a biomarker of cellular injury was to translate 
insights from our in vitro results to an in vivo model of mouse IRI. cfDNA is readily 
detected in serum following kidney IRI; B6 IRI serum contains considerably more cfDNA 
than serum from B6 sham surgery. These findings were supported by results in which 
serum creatinine was also significantly elevated in B6 IRI when compared to sham control. 
This finding supports the concept that cfDNA is a biomarker of cellular injury that occurs 
during IRI. In support of this, DKO mice, in which caspase-8 and RIPK3 are genetically 
knocked out, show significantly reduced levels of both serum cfDNA and creatinine when 
compared to wild type B6 IRI, and are comparable to cfDNA and creatinine levels in sham 
controls. It is worth noting that RIPK3-/- IRI mice trend towards lower serum cfDNA levels 
than IRI in B6 mice, but statistical significance was not achieved. Larger test numbers may 
have clarified this. This suggests that inhibition of necroptosis alone may attenuate but not 
abrogate IRI, in keeping with previous results reported. However, inhibition of both 
apoptosis and necroptosis together appears to be much more effective. Indeed, these results 
make sense when taken into context with results in which MVECs with both apoptosis and 
necroptosis inhibition (TSIN treated) showed a drastic reduction in cell death when 
compared to cells undergoing apoptosis (TS) or necroptosis (TSI) alone. Taken together, 
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these results indicate that any attempts to reduce cell death during IRI should practically 
target both apoptosis and necroptosis, as inhibiting only one form of cell death will likely 
not be sufficient. It is also worth noting that these findings are likely not applicable just to 
IRI in a transplant setting. Any disease that involves ischemia, such a myocardial infarcts 
or strokes, may similarly benefit from simultaneous inhibition of apoptosis and 
necroptosis. 
 Lastly, RIPK3-/- IRI mice showed serum creatinines that were comparable to sham, 
while cfDNA levels were significantly higher than those using sham surgery. This finding 
lead us to consider that cfDNA may be a more sensitive biomarker of kidney injury than 
serum creatinines, which are currently used clinically as measures of kidney dysfunction. 
In order to investigate this possibility further, we employed a temperature-dependant IRI 
model in order to characterize cfDNA release during subclinical IRI. 
Indeed, as temperature during IRI was increased in 4°C intervals, from 24°C to 
36°C, significant differences in serum cfDNA were detected at each interval, with cfDNA 
increasing as temperature increases. This finding is valuable for two reasons. Firstly, it is 
clear that the temperature at which ischemia is induced plays a significant role in the degree 
of injury to the kidney, with small reductions in temperature resulting in measurable 
reductions in cell death. These findings recapitulate an important finding by Niemann et 
al. (134), showing that mild hypothermia in DCD donors significantly reduced the rate of 
delayed graft function among kidney transplant recipients. Secondly, it is clear that cfDNA 
is a very sensitive biomarker of injury, as serum levels were reduced even with small 
reductions in IRI model temperatures. Furthermore, cfDNA was detectable in subclinical 
IRI at 24°C in which serum creatinines remained in the normal range 24 hours post-IRI. 
At 48 hours post-IRI, cfDNA was detectable in subclinical IRI at 24-28°C, in which serum 
creatinines also remained in the normal range. These findings indicate that cfDNA is a 
more sensitive biomarker of kidney cellular injury than serum creatinine levels. These 
findings are particularly important because serum creatinine measurements are the current 
gold standard for monitoring graft function in kidney transplant recipients (110), but it has 
been noted that deterioration in graft function can only be detected after significant damage 
to the graft has occurred (111). Therefore, a more sensitive biomarker of kidney injury that 
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can be detected before significant damage to the graft occurs would be very valuable. 
Furthermore, subclinical rejection (graft damage in the absence of a measureable increase 
in serum creatinine) is currently detected exclusively via surveillance biopsies that are both 
costly and invasive (112). Since cfDNA can be detected in both the blood and urine of 
transplant recipients (113), and because we have shown that it is more sensitive than serum 
creatinines, cfDNA shows promise as a less invasive and more sensitive method of 
detecting subclinical rejection. It is also worth noting that differences in both cfDNA and 
creatinine are more pronounced at 24 hours than 48 hours post-IRI. This is logical as the 
more time that has passed following injury, the more time there is for phagocytes to clear 
DAMPs such as cfDNA. It remains to be tested whether the changes we observed with 
cfDNA in the absence of a change in serum creatinine has an impact on long term kidney 
function. This will be key to any strategy that uses cfDNA as a surrogate measure of injury 
4.3 cfDNA is a Biologically Active DAMP that is Capable of 
Exacerbating Inflammation and IRI 
After characterizing the release of cfDNA during programmed cell death in vitro 
and during IRI in vivo, our third and final objective was to determine if cfDNA is capable 
of activating NK cells in vitro. Previous research has shown that cfDNA is capable of 
binding to TLR9 to induce the secretion of TNFα and IL-10 in haMSCs (126), 
demonstrating clearly that cfDNA has the potential of being immunogenic. Furthermore, 
NK cells are well-described effectors of IRI (28, 31), however, they are currently not 
targeted directly by any currently used immunosuppression therapies clinically (38), and 
the effect of cfDNA on NK cells has not been described.  
 Our data clearly indicate that NK cells upregulate key activation markers Granzyme 
B, IFNγ, and TNFα when treated with cfDNA. In particular, Granzyme B and IFNγ mRNA 
expression increased markedly from naïve controls when treated. The effect of cfDNA was 
the same when isolated from the serum of B6 mice 48 hours post-IRI, as well as cfDNA 
isolated from B16-BIMs and B16-FADD-DD cell lines, which were genetically induced 
(via tetracycline) to undergo apoptosis and necrosis, respectively. Importantly, this effect 
was abrogated completely with the addition of DNase, and no activation was observed 
when cells were treated with the elution buffer used to extract cfDNA. It is noteworthy that 
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a significant increase in mRNA expression was not detected for any of the activation 
markers in NK cells treated with 50ng/mL cfDNA. However, a clear trend is evident, and 
statistical significance may have been achieved with a higher n value. TNFα mRNA 
expression increased only modestly with the addition of cfDNA from B6 IRI mice and 
from apoptotic B16-BIMs cell culture, but not from necrotic cfDNA extracted from B16-
FADD-DD cell culture. Again, a clear trend is evident and statistical significance may have 
been achieved with a higher n value, if time had permitted. Lastly, it is clear that PolyIC is 
a more potent activator of NK cells than is human IL-2. This finding may not have obvious 
biological implications, but it supports the notion that PolyIC may represent the near 
maximal positive control for NK cell activation in future experiments.  
 Prior to these experiments, we had considered whether cfDNA released from 
necrotic vs apoptotic cells would differ in its ability to activate NK cells. Our result clearly 
shows that the source of cfDNA does not appear to be relevant and that cfDNA released 
from apoptosis and necroptosis activate NK cell function equivalently at the same dose. 
More cfDNA is released by necroptotic cells than apoptotic cells, and therefore necroptosis 
may be a more important target than apoptosis from this quantitative standpoint, however, 
as explained above, strategies that target both apoptosis and necroptosis simultaneously 
will likely be most effective. 
The cumulative injuries accrued during IRI, from ischemic conditions to the release 
of reactive oxygen species before and upon reperfusion, cause cells of the kidney allograft 
to undergo various forms of programmed cell death, which cumulatively contribute to 
further injury and organ loss (47-51). During this injury, intracellular DAMPs, including 
cfDNA, as well as heat shock proteins (HSPs) and high-mobility group box-1 (HMGB1), 
are released and enter the circulation to have local and distant effects (103). We have 
demonstrated the release of cfDNA with programmed cell death in vitro and in vivo and 
that cfDNA can activate NK cells. Therefore, as IRI causes cell death, which in turn leads 
to DAMP release that can activate NK cells and potentiate their function as cytotoxic 
effectors with IRI, sets up an auto-amplification program that will result in more cell death, 
and the further release DAMPs (Figure 10). It is intuitive that strategies that can reduce 
cell death and the resultant DAMP release during IRI would be very beneficial. It is also 
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evident from these results that strategies to prevent cfDNA from activating NK cells would 






















Figure 10. Proposed mechanism of inflammatory cycle during kidney IRI. 
Transplantation-associated IRI causes cell death in the kidney allograft, leading to the 
release of cfDNA from apoptotic and necroptotic cells. Released cfDNA binds to and 
activates NK cells, which as cytotoxic effector cells will result in more cell death and 






4.4 Strategies to Reduce cfDNA Release 
In an attempt to block the cyclical inflammatory pattern of cell death leading to 
DAMP release leading to immune cell activation and more cell death, it is perhaps most 
logical to stop this problem at its start. Thus, any strategy that prevents IRI will be 
beneficial, although in the case of transplant it is more complex in that surgical removal of 
the organ from the donor is always required. Our results also support that inhibition of both 
apoptosis and necroptosis simultaneously may be of impact clinically. Therefore, strategies 
to simultaneously inhibit apoptosis and necroptosis in kidney allografts should be explored. 
It is worth noting that any of these strategies would likely be limited to early time periods, 
as permanent elimination might result in cancerous cell growth. It is noted that in the case 
of necroptosis, there is no cancer phenotype for RIPK3 null mice, which suggests that the 
risk for cancer might be exaggerated. In contrast, long-term inhibition of caspase-8 has not 
been tested in a genetic deletion, as this is embryonic lethal. Transient inhibitors of 
apoptosis and necroptosis could certainly be considered as additives to organ perfusion 
solutions. Our results as well as others also show a temperature-dependant reduction in 
tissue injury, with less cell death occurring as the temperature at which ischemia occurs is 
lowered. This is consistent with the current trend in clinical transplantation towards using 
sub-normothermic perfusion of to-be-transplanted donor organs.  
4.5 Strategies to Reduce the Biological Activity of cfDNA 
As we have shown that cfDNA activates NK cells, which are known effectors of 
IRI (28), it would also be prudent to explore strategies that prevent cfDNA from activating 
NK cells. Previous work has shown that cfDNA is more GC-rich than genomic DNA 
(perhaps because GC-rich regions of DNA are more stable in blood) (125), and cfDNA is 
therefore capable of binding to and activating TLR9 (126). NK cells are known expressers 
of TLR9, and TLR9 activation in NK cells results in the induction of cytotoxicity and 
cytokine release (135). Therefore, it would be useful to explore options to inhibit TLR9 in 
NK cells in the setting of IRI. However, much like the inhibition of cell death pathways, 
permanent inhibition of TLR9 in organ transplant recipients may not be desirable as it 
would further suppress immunity and increase vulnerability to bacteria and viruses. 
Therefore, transient antagonism of TLR9 could be considered before and immediately after 
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transplantation in order to prevent NK cell activation during IRI. As TLR9 is an 
intracellular receptor, it would also be useful to study the uptake of cfDNA into NK cells. 
Perhaps this is another avenue of intervention that should be explored. Furthermore, as 
cfDNA is clearly an activator of immune effector cells, perhaps simply adding DNase to 
organ perfusion solutions will limit immune cell activation and subsequent cell death in 
the perfused organ. 
Lastly, an elegant approach to limiting cfDNA-induced inflammation in a mouse 
model of rheumatoid arthritis (RA) was described by Liang et al. (136). As cfDNA is 
obviously anionic (due to the negatively charged phosphate backbone of DNA), Liang et 
al. utilized 40nm cationic nanoparticles (cNP) to scavenge cfDNA and prevent activation 
via TLR9 on various immune effector cells. Injection of cNPs inhibited the activation of 
monocytes in the synovial fluid, and relieved bone and cartilage damage, as well as tissue 
and ankle swelling. A similar model of cNP injection could be explored using a mouse 
transplant model to assess its effect on acute graft injury.  
4.6 Conclusions 
Our data indicate that cfDNA is released from MVECs during apoptosis and 
necroptosis in vitro. While necroptotic MVECs release more cfDNA than apoptotic 
MVECs, biological effects are similar in NK cell activation, and any differences elicited 
may be due to quantitative rather than qualitative issues. cfDNA was also readily detected 
in serum following kidney IRI in a mouse model in vivo, with levels in DKO mice, 
incapable of undergoing apoptosis or necroptosis, comparable to sham controls. We also 
show that cfDNA is a particularly sensitive biomarker of injury, as serum levels were 
reduced even with small reductions in IRI model temperatures, with cfDNA being 
detectable at low temperatures in which serum creatinines remained in the normal range. 
Lastly, we have shown that NK cells, well described effectors of IRI, upregulate key 
activation markers Granzyme B, IFNγ, and TNFα when treated with cfDNA. Therefore, 
cfDNA is not only a biomarker of kidney injury; it also has inflammatory properties. 
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4.7 Future Directions 
As cfDNA appears to be a very sensitive marker of subclinical cellular injury and 
IRI, it is plausible that one day we may see the development of real time cfDNA sensors 
that can be employed during ex vivo organ perfusion. This is an obvious engineering 
challenge, but if executed, would provide a clinician with real time measures of cfDNA as 
a proxy of graft viability. This would allow a clinician to make real time judgement calls 
on whether a potential donor organ (particularly from deceased donors) is of sufficient 
quality for transplantation. Furthermore, as cfDNA is particularly sensitive, it is possible 
for the development of liquid biopsies to replace current surgical biopsies, where 
subclinical acute rejection can be diagnosed at an earlier time point than is currently 
possible. This would allow for earlier intervention during subclinical acute rejection, and 
is also less invasive for the patient.  
More work is also required to understand the mechanism of cfDNA incorporation 
into NK cells as well as other immune effector cells such as macrophages and monocytes. 
As mentioned, cfDNA binds to TLR9 which is an intracellular receptor. What is not clear 
is how cfDNA gets from the blood into the cytoplasm of NK cells. There are many 
receptors on the surface of NK cells that may allow for cfDNA incorporation into the 
cytoplasm, and these receptors are potential therapeutic targets. Lastly, similar to the 
injection of cNPs into a RA model, a similar method could be explored in a mouse model 
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